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Obesity correlates with hematologic malignancies includingleukemias, but risk of specific leukemia subtypes like acutepromyelocytic leukemia and underlying molecular mechanisms are
poorly understood.  We explored multiple datasets for correlation between
leukemia, body mass index (BMI) and molecular features. In a population-
based study (n=5.2 million), we correlated BMI with promyelocytic
leukemia, and other acute myeloid, lymphoid or other leukemias. In cross-
sectional studies, we tested BMI deviation in promyelocytic leukemia trial
cohorts from that expected based on national surveys. We explored The
Cancer Genome Atlas for transcriptional signatures and mutations enriched
in promyelocytic leukemia and/or obesity, and confirmed a correlation
between body mass and FLT3 mutations in promyelocytic leukemia
cohorts by logistic regression.  In the population-based study, hazard ratio
per 5 kg/m2 increase was: promyelocytic leukemia 1.44 (95%CI: 1.0-2.08),
non-promyelocytic acute myeloid leukemias 1.17 (95%CI: 1.10-1.26), lym-
phoid leukemias 1.04 (95%CI: 1.0-1.09), other 1.10 (95%CI: 1.04-1.15). In
cross-sectional studies, body mass deviated significantly from that expected
(Italy: P<0.001; Spain: P=0.011; USA: P<0.001). Promyelocytic leukemia
showed upregulation of polyunsaturated fatty acid metabolism genes.
Odds of FLT3 mutations were higher in obese acute myeloid leukemias
(odds ratio=2.4, P=0.007), whether promyelocytic or not, a correlation con-
firmed in the pooled promyelocytic leukemia cohorts (OR=1.22, 1.05-1.43
per 5 kg/m2).  These results strengthen the evidence for obesity as a bona fide
risk factor for myeloid leukemias, and in particular APL. FLT3 mutations
and polyunsaturated fatty acid metabolism may play a previously under-
appreciated role in obesity-associated leukemogenesis.
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ABSTRACT
Introduction
The etiology of acute myeloid leukemia (AML) remains poorly understood.
Genetic predisposition or clear exposure to environmental mutagenic agents
(smoking, benzene, radiation, prior chemotherapy) can be demonstrated only in a
minority of cases.1 Age is an independent risk factor, probably linked to the pro-
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gressive mutation accumulation and clonal stem cell
expansion that accompanies aging.2 Although obesity has
recently emerged as a prominent risk factor for a variety of
solid tumors,3 its impact on hematologic neoplasms has
received less attention. A moderate but consistently posi-
tive correlation between body mass index (BMI) and inci-
dence of leukemias has been identified in observational
studies,4-6 yet none of the collected evidence has been con-
sidered sufficiently strong to consider obesity as a bona fide
risk factor for AML.3,7 Most studies did not distinguish
between myeloid/lymphoid and acute/chronic forms, nor
between genetic subtypes within each form. AML is rec-
ognized as a highly heterogeneous disease with genetical-
ly diverse subtypes.8 Subtypes have radically different out-
comes and, similarly, their risk may be differentially
affected by environmental factors. Identification of sub-
type-specific risk associations, however, is made difficult
by their rarity.  
A genetic subset of AML, acute promyelocytic leukemia
(APL), is characterized by a specific chromosomal translo-
cation (t15;17), homogeneous biology and response to
clinical agents all-trans retinoic acid (ATRA) and arsenic
trioxide, which have made it the most curable form of
AML to date.9 We previously demonstrated that the risk of
relapse after ATRA/idarubicin is significantly increased in
overweight/obese APL patients.10 In the present report, we
investigated the association of overweight/obesity with
the risk of developing APL and other leukemias. We
describe the results of multiple studies across four western
populations with significantly different dietary regimens
and prevalence of obesity. All the  studies demonstrated
increased risk of developing APL in overweight/obesity
subjects. In an effort to generate mechanistic hypotheses
to explain this relationship, we analyzed transcriptomic
and mutational data from the AML project in The Cancer
Genome Atlas (TCGA)11 and identified alterations selec-
tively associated with obesity and/or APL which may be
involved in obesity-associated leukemogenesis. 
Methods
UK population-based study: data collection
and statistical methods
Full details of the methods for the UK population study were
described previously.6 The study was approved by the London
School of Hygiene and Tropical Medicine Ethics Committee. To
identify outcomes of specific leukemia sub-types, Clinical Practice
Research Datalink (CPRD) clinical records were searched for codes
relating to specific leukemia subgroups. We controlled for multiple
co-variates at time of the BMI record(s): age, smoking status, alco-
hol use, previous diabetes diagnosis, index of multiple depriva-
tion, calendar period, and stratified by gender. We excluded peo-
ple with missing smoking [49,206 of 5.24 million (0.9%)] and alco-
hol [394,196 of 5.24 million (7.5%)] status. Confidence intervals
(CI) in Figure 1 are presented at the 99% level; all other CIs are
presented at the 95% level.
Cross-sectional studies: data collection and statistical
methods
Acute promyelocytic leukemia cases from Spain were extracted
from the PETHEMA database to include 414 cases diagnosed
between 1998 and 2012. APL cases from Italy, where 134 adult
patients were treated under the AIDA protocol, were included in
the previously described cohort.10 APL cases from the USA includ-
ed the entire cohort of the published AML The Cancer Genome
Atlas (TCGA) project11 (n=20) plus 22 additional APL cases, unse-
lected for any clinical variable, diagnosed at Washington
University, St. Louis, MO, USA (Expanded TCGA cohort). For all
case cohorts, BMI was measured at the time of diagnosis.
Data collection was approved by the Research Ethics Board of
each participating institution, as referenced.11-14 Data sources for
expected BMI in the local population are described in the Online
Supplementary Appendix. 
We compared the distribution of BMI observed in the three APL
case cohorts to the distribution of BMI expected in the general pop-
ulation of the same countries. Specifically, to calculate the expected
distribution of BMI in Italy, we used data from the Italian National
Institute of Statistics,14 and we selected the area of Lazio, where the
APL cases were diagnosed, in the years 2000-2010. For Spain, we
used data from the Eurostat,15 and we selected the general popula-
tion of Spain in the year 2008, the only year available. For both
Italy and Spain, the expected BMI distribution was calculated using
the available age- and gender-specific BMI distribution of the gen-
eral population classified into three categories (<25,  25-29.9,  ≥30).
For the USA, we used the 2009-2010 data from the American
National Health and Nutrition Examination Survey.16 The expected
BMI distribution was calculated using the available race-, age-, and
gender-specific BMI distribution of the general population classi-
fied into four categories (<25, 25-29.9, 30.0-34.9, ≥35).
The global null hypothesis that the observed counts did not dif-
fer from the expected ones across the BMI categories was tested
in a null Poisson regression model, where the observed counts
were considered as dependent variable and the expected counts as
the offset. BMI was included in the model  as an ordinal variable
to test the log-linear relationship between BMI and the observed
to expected ratio (i.e. to test for linear trend). Pearson's χ2 goodness
of fit test P-value was reported.
Expression data analysis
Expression data (RPKM matrix) were down-loaded from the
AML TCGA data portal. Cases with available RNAseq, BMI and
French-American-British (FAB) classification data (177 of 200)
were used in the present study. Cases were classified by FAB in
"APL" (FAB="M3") and "non-APL" (FAB ≠ "M3"), and by BMI in
"obese" (BMI ≥ 30) and "non-obese" (BMI < 30). Genes with < 0.2
reads per kilo base per million mapped reads (RPKM) in at least
75% of patients were removed.11 The Quantitative Set Analysis
for Gene Expression method, as implemented in the quSAGE
package15 in the R programming language (v3.2.3), was used to
conduct supervised gene set enrichment analysis. For each
expressed gene, the quSAGE algorithm calculates a probability
density function (PDF) of differential expression between two
groups of samples. For each gene set, it then calculates "activity",
i.e. the mean difference in log-expression of individual genes
included in a gene set. Gene sets with False Discovery Rate (FDR)
< 0.05 were considered significant. We focused on the Kyoto
Encyclopedia of Genes and Genomes (KEGG)  and chemical and
genetic perturbations (CGP) gene set collections, down-loaded
from MSigDB (http://software.broadinstitute.org/gsea/msigdb/).
The CGP collection was used to confirm enrichment of previously
identified APL-specific gene signatures16 (Online Supplementary
Table S1). We focused on the KEGG collection, as it is enriched for
metabolism-associated gene annotations.16 The script to generate
the present results is available on request. 
Mutational data analysis
For the analysis of the TCGA data, mutational data were
retrieved from the TCGA AML paper,11 and AML driver genes
(restricted to those with at least 2 mutations in the dataset) were
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down-loaded from IntOgen.17 For each gene, different mutations
were conflated so that gene status in each patient was either
"mutated" or "wild-type". For each gene, we then calculated the
number of mutated or wild-type patients in the obese or non-
obese groups, and calculated odds ratios (OR), 95% confidence
intervals (CI), and P-values by Fisher's test with Benjamini-
Hochberg correction. Only genes with >1 mutation in the dataset
were considered, using the fdsm package in R.
For the analysis of the retrospective cohort, FLT3 Internal
Tandem Duplication (ITD) mutational data were provided by the
referring centers. Logistic regression was used  to calculate OR
with 95%CI.
Further details of the methods used are provided in the Online
Supplementary Appendix.
Results
Population-based cohort study in the UK
Overall characteristics of the 5.24 million UK adults
included in this study have been described previously.6 A
total of 5,833 subjects with a diagnosis of “leukemia” over
the observational time were included in the present analy-
sis. These events were further classified in the following
groups: “APL” (n=26), “non APL-AML” (n=1,012), lym-
phoid leukemias (“LL”; n=2,823), and “other” (n=1,972).
Median time lapse between BMI measurement and diag-
nosis was similar across subgroups (APL: 1,810 days;
AML: 2,280 days; LL: 1,928 days; other: 1,894 days).
We fit BMI as a three-knot cubic spline and as a linear
term. There was no evidence of non-linearity (P=0.94),
suggesting that the relationship was best described by the
linear model. After adjusting for co-variates, per each 5
kg/m2 increase we obtained hazard ratios (HR) of 1.44 for
Obesity and risk of AML/APL, FLT3 muts and fat metabolism
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Figure 1. Relationship between body mass index (BMI) and log-hazard ratio (HR) for leukemias in the UK population. (A) Acute promyelocytic leukemia (APL);  (B)
other acute myeloid leukemia (AML); (C) lymphoid leukemias; (D) all leukemias. Plots show mean (dark line) ± 95% confidence intervals (shaded area).
Table 1. Hazard ratios from the UK population study.
Disease         N. of          Adjusted HR (per 5 kg/m2                95% CI
                     events                 increase in BMI)
APL                      26                                     1.44                                        1.00, 2.08
AML                  1,012                                  1.17                                        1.10, 1.26 
LL                      2,823                                  1.04                                        1.00, 1.09
Other               1,972                                  1.10                                        1.04, 1.15
N: number; HR: hazard ratio; BMI: body mass index; CI: confidence interval; APL: acute
promyelocytic leukemia; AML: acute myeloid leukemia; LL: lymphoid leukemias.
A B
C D
APL (95%CI: 1.0-2.08), 1.17 for non APL-AML (95%CI:
1.10-1.26), 1.04 for LL (95%CI: 1.0-1.09), and 1.10 for
other leukemias (95%CI: 1.04-1.15) (Table 1 and Figure 1).
Stratification by gender suggested a stronger effect for
male gender in APL (HR 1.82, 95%CI: 1.10- 3.00 vs. female
HR 1.19, 95%CI: 0.67-1.98), although the sample size
becomes very small (n=13 each). Together, these results
suggest that higher BMI is associated with increased risk
of all sub-types of leukemia, particularly APL.
Cross-sectional studies in Italian, Spanish and US trial
cohorts
Though APL showed the strongest association with
higher BMI in the cohort analysis  described above, results
were not conclusive due to the small number of cases
identified (n=26) and the consequently wide confidence
intervals. To strengthen the evidence, we carried out ret-
rospective case-control studies using cohorts of APL
patients from national registries of clinical trials from
Spain (PETHEMA) and Italy (GIMEMA), and patients
from the US-based AML genome sequencing study (the
AML TCGA cohort with 22 additional cases characterized
at Washington University, St Louis, MO). In all three
groups, APL diagnosis was established using gold standard
diagnostic procedures. 
Demographic characteristics of the three case cohorts
(Italy n=134, Spain n=414 and USA n=42) are described in
Table 2. Gender (female 53.0%, 55.2%, 50%, respectively)
and age (median of 45, 45, 47 years, respectively) were sim-
ilarly represented. Information on ethnicity was unavailable
for the Spanish and Italian cohorts, whereas white, black
and hispanic ethnicities were represented in the US cohort.
To generate control groups for comparison, we obtained
anthropometric data from epidemiological surveys of the
general population in the different countries. As the preva-
lence of obesity has increased dramatically in most coun-
L. Mazzarella et al.
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Table 2. Description of the cross-sectional cohorts.
                                                                                                           Italy                                         Spain                                            USA
                                                                                                          n=134                                      n=414                                          n=42
Age                                                    18 - 35                                                       46 (34.3%)                                      113 (27.3%)                                          13 (31.0%)
                                                           36 - 50                                                       34 (25.4%)                                      145 (35.0%)                                          12 (28.6%)
                                                           51 - 65                                                       40 (29.9%)                                      102 (24.6%)                                          11 (26.2%)
                                                             > 65                                                        14 (10.4%)                                       54 (13.0%)                                            6 (14.3%)
                                                    Median (IQR)                                                45 (31-57)                                        45 (34-57)                                            47 (33-60)
Gender                                              Male                                                        63 (47.0%)                                      227 (54.8%)                                          21 (50.0%)
                                                          Female                                                      71 (53.0%)                                      187 (45.2%)                                          21 (50.0%)
Year of diagnosis                  Median (range)                                        2002 (1997-2010)                            2003 (1996-2012)                               2007 (2001-2011)
Race                                                  White                                                                -                                                          -                                                      36 (85.7)
                                                            Black                                                                 -                                                          -                                                       5 (11.9)
                                                         Hispanic                                                              -                                                          -                                                        1 (2.4)
BMI                                            Median (IQR)                                                26 (23-28)                                        26 (23-29)                                            34 (28-39)
IQR: interquartile range; BMI: body mass index; n: number.
Table 3. Observed body mass index (BMI) distribution in acute promyelocytic leukemia  (APL) cases and expected BMI distribution in general
population (percentages in brackets).
                                                                          All                                                             Males                                                        Females
Italy              BMI                      Obs                   Expa               P                     Obs                 Expc               P                  Obs                  Expdc              P
                        <25.0                   48 (35.8%)         77.8 (58.0%)     <0.001              16 (25.4%)       29.0 (46.0%)      <0.001           32 (45.1%)         48.8 (68.7%)      <0.001
                      25.0-29.9                 71 (53.0%)         44.8 (33.4%)                                42 (66.7%)       28.0 (44.5%)                              29 (40.8%)         16.8 (23.6%)            
                        ≥30.0                   15 (11.2%)          11.4 (8.5%)                                   5 (7.9%)           6.0 (9.5%)                                10 (14.1%)           5.5 (7.7%)              
                         Total                           134                        134                                                63                        63                                               71                          71                     
Spain            BMI                      Obs                   Expa               P                     Obs                 Expc               P                  Obs                  Expdc              P
                        <25.0                  172 (41.5%)       189.9 (45.9%)      0.011                79 (34.8%)       85.0 (37.4%)        0.130             93 (49.7%)        104.9 (56.1%)      0.033
                      25.0-29.9               156 (37.7%)       158.1 (38.2%)                               99 (43.6%)      103.2 (45.5%)                             57 (30.5%)         55.9 (29.4%)            
                        ≥30.0                   86 (20.8%)         66.0 (15.9%)                                49 (21.6%)       38.8 (17.1%)                              37 (19.8%)         27.2 (14.6%)            
                         Total                           414                        414                                               227                      227                                             187                        187                    
USA              BMI                      Obs                   Expb               P                     Obs                 Expc               P                  Obs                  Expdd              P
                        <25.0                     2 (4.8%)           12.8 (30.6%)     <0.001                1 (4.8%)          5.3 (25.4%)         0.002               1 (4.8%)            7.5 (35.7%)        0.003
                      25.0-29.9                 13 (31.0%)         13.7 (32.6%)                                 5 (23.8%)         7.9 (37.7%)                                8 (38.1%)           5.8 (27.6%)             
                      30.0-34.9                 12 (28.6%)          8.6 (20.5%)                                  9 (42.9%)         4.8 (23.0%)                                3 (14.3%)           3.8 (18.0%)             
                        ≥35.0                   15 (35.7%)          6.9 (16.3%)                                  6 (28.6%)         2.9 (13.9%)                                9 (42.9%)           3.9 (18.8%)             
                         Total                            42                          42                                                 21                        21                                               21                          21                     
Expected frequencies were obtained from the body mass index (BMI) distribution in the general population of the area of the acute promyelocytic leukemia (APL) cases, period
of APL diagnosis and in addition: aage class and gender; bage class, gender and race; cage class; dage class and race. Obs: observed.
tries in the last decades (especially in the USA), we
obtained data that were as close as possible to the median
year of diagnosis (2002 for Italy, 2003 for Spain, 2007 for
the USA) (Table 3; see also Methods section). 
In all three cohorts, there was strong evidence that the
observed BMI distribution for cases across World Health
Organization (WHO) BMI classes was different from that
expected under the null hypothesis of no association
(Italy: P<0.001; Spain: P=0.011; USA: P<0.001) (Table 3) in
gender-, age-, and ethnicity- (for USA) matched controls.
In particular, in all three datasets, there were more cases
than expected in the higher BMI groups, irrespective of
gender in all cohorts apart from Spain, in which signifi-
cance was not reached for males (P=0.130) despite a simi-
lar trend (Table 3).
Correlation of TCGA transcriptomics data with body
mass index and acute myeloid leukemia subtype
The availability of the TCGA dataset prompted us to
search for signatures that could suggest a mechanistic
rationale for the association between APL and obesity. We
interrogated available AML transcriptomes with super-
vised gene set enrichment analysis using quSage.15
Focusing on the KEGG gene set collection, APL was asso-
ciated with increased activity of 13 and decreased activity
of 64 out of 186 gene sets (Table 4, Figure 2A and Online
Supplementary Table S2). Intriguingly, among significantly
up-regulated gene sets, we found pathways associated
with the metabolism of long-chain unsaturated fatty acids
(linoleic and arachidonic), which are precursors of
eicosanoids mediating inflammation-associated cancers.18
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Figure 2. Differential activities of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and insulin/leptin receptors in the M3 versus non-M3 quSage com-
parison in The Cancer Genome Atlas (TCGA). (A) Activity score with 95% Confidence Intervals (CI) of 186 KEGG gene sets; significant gene sets are color-coded in
red (if up-regulated) or green (if down-regulated). (B) Insulin/IGF1 receptor pathway and leptin receptors. Mean ± 95% confidence interval are plotted.
Table 4. Significantly up-regulated Kyoto Encyclopedia of Genes and Genomes (KEGG)  pathways in acute promyelocytic leukemia versus acute
myeloid leukemia in The Cancer Genome Atlas (TCGA).
pathway.name                                                                                                                      log.fold.change                    P                                FDR
KEGG_RENIN_ANGIOTENSIN_SYSTEM                                                                                                         0.6503                              0.0023                                 0.0093
KEGG_LINOLEIC_ACID_METABOLISM                                                                                                          0.6381                              0.0002                                 0.0010
KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE                                                 0.4217                              0.0000                                 0.0000
KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES                        0.3391                              0.0003                                 0.0017
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM                                                           0.3258                              0.0009                                 0.0039
KEGG_ARACHIDONIC_ACID_METABOLISM                                                                                                 0.3221                              0.0037                                 0.0130
KEGG_GLYCOSAMINOGLYCAN_DEGRADATION                                                                                          0.3208                              0.0000                                 0.0001
KEGG_HISTIDINE_METABOLISM                                                                                                                     0.2996                              0.0044                                 0.0148
KEGG_ARGININE_AND_PROLINE_METABOLISM                                                                                       0.2582                              0.0001                                 0.0008
KEGG_LIMONENE_AND_PINENE_DEGRADATION                                                                                    0.1662                              0.0087                                 0.0250
KEGG_CARDIAC_MUSCLE_CONTRACTION                                                                                                  0.1475                              0.0084                                 0.0245
KEGG_PROTEIN_EXPORT                                                                                                                                  0.1439                              0.0066                                 0.0204
KEGG_PATHWAYS_IN_CANCER                                                                                                                          0.1346                              0.0169                                 0.0428
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Also noticeable was the APL-associated upregulation of
insulin and insulin-like growth factor (IGF1) receptors, but
not leptin receptor (Figure 2B); insulin signaling-associated
pathways were also specifically up-regulated in obese ver-
sus non-obese APL patients ("type II diabetes mellitus" and
"insulin signaling") (Online Supplementary Table S2).
No pathway was significantly enriched in obese versus
non-obese patients among non-M3 cases.
Correlation of mutational data with body mass index
We then asked whether obesity is associated with spe-
cific driver mutations in AML in the TCGA cohort. Out of
23 established driver genes mutated at least twice in the
cohort, mutations in FLT3 were positively associated with
obesity (33 of 88 obese vs. 22 of 110 non-obese; OR=2.4,
FDR=0.16, P=0.007) (Figure 3 and Online Supplementary
Table S3). The correlation remained statistically significant
both in non-APL AML (27 of 49 obese vs. 22 of 102 non-
obese; OR=2, P=0.04,) and in APL (6 of 12 obese vs. 0 of 8
non-obese; P=0.04). When we analyzed the two main
classes of FLT3 mutations separately [tyrosine kinase
domain (TKD) and internal tandem duplication (ITD)], the
association held statistically significant for ITD (24 of 88
obese vs.  14 of 110 non-obese; OR=2.6, P=0.01) but not
for TKD (9 of 88 obese vs.  8 of 110 non-obese; P=0.6). In
APL, where all FLT3 mutations were ITD, the correlation
remained statistically significant (6 of 12 obese vs. 0 of 8
non-obese; P=0.04). In non-APL AML, with 32 ITD and 17
TKD, overall FLT3 mutations were still significantly
enriched in obese patients ((27 of 49 obese vs.  22 of 102
non-obese; OR=2, P=0.04) but not when analyzed sepa-
rately (P=0.11 for ITD and 0.44 for TKD).  
We then attempted to validate this finding in the APL
cohorts, for which data on the most representative
FLT3ITD mutation (ITD) were available (Table 5). In the
pooled analysis (163 mutated patients, of a total 569), OR
of having a FLT3 ITD was 1.22 (95%CI: 1.05-1.43) per each
5 kg/m2 increase. In the individual cohorts, results were sig-
nificant in the Italian (30 of 114 mutated,  OR=2.35,
95%CI: 1.25-4.42) and US (14 of 41 mutated, OR=1.44,
95%CI: 0.93-2.24) cohorts, but not in the Spanish (119 of
414 mutated, OR=1.09, 95%CI: 0.89-1.33).
Discussion
Here we provide substantial evidence for an association
between elevated BMI and risk of developing AML. The
risk was particularly high with the APL subtype, with an
estimated 44% HR increase per each 5 kg/m2. This was
qualitatively confirmed by comparing expected versus
observed BMI distributions in APL cohorts across three
western countries (the USA, Spain and Italy) with different
obesity prevalence and dietary habits. In addition, we pro-
vide hypothesis-generating evidence for molecular mecha-
nisms underlying such an association, in particular, the
possible involvement of pro-inflammatory fatty acid
metabolism and mutations of the tyrosin kinase FLT3.
Our epidemiological results expand a growing body of
literature identifying overweight/obesity as a bona fide risk
factor for leukemias. The most recent meta-analysis
reported an adjusted relative risk of 1.14 (95%CI: 1.04-
1.26; P=0.008) for AML overall.5 Despite the growing evi-
dence, the notion of obesity as a risk factor for leukemia
remains widely overlooked.7 Among the highly heteroge-
neous AML subtypes, APL is the most clinically and bio-
logically coherent. We and others previously showed that
in APL, but not in other AML, an elevated BMI significant-
ly affects outcome.10,19 This is also in line with the few ret-
rospective studies that have assessed APL as a separate
disease entity.20,21 No study had addressed this question
prospectively, a task made difficult by the rarity of the dis-
ease, but made possible in our case by the very large study
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Figure 3. Association between obesity and FLT3 mutations. (A) Bubble plot rep-
resenting Odds Ratio versus -logP value (mLogPval) of any mutation in 23 driver
genes in The Cancer Genome Atlas (TCGA) acute myeloid leukemia  cohort. FLT3
(in red) is the only gene with False Discovery Rate (FDR) < 0.25. Bubble size
reflects the number of obese patients with a mutation. Data are tabulated in
Online Supplementary Table S3.
Table 5. Logistic regression of body mass index (BMI) and FLT3 ITD mutations.
BMI                            All 3 cohorts 163/569a                        ITALY 30/114a                   SPAIN 119/414a                                      USA 14/41a
                                            OR (95% CI)                                   OR (95% CI)                        OR (95% CI)                                         OR (95% CI)
5 unit increase                       1.22 (1.05-1.43)                                      2.35 (1.25-4.42)                        1.09 (0.89-1.33)                                             1.44 (0.93-2.24)
≥ 25 vs. <25b                                        -                                                   4.40 (1.63-11.9)                        1.15 (0.75-1.78)                                                           -
≥ 30 vs. <30b                                        -                                                                 -                                                   -                                                           6.46 (1.21-34.5)
aMutations / All patients. bGiven the small number of obese patients in Italy and Spain, we compared overweight/obese patients versus normal weight patients (i.e. BMI ≥ 25 vs.
<25). Given the small number of normal weight patients in the USA, we compared obese patients versus non-obese patients (i.e. BMI ≥ 30 vs. <30). OR: odds ratios; CI: confidence
intervals.
population (5.2 million). The largest prospective study to
date (EPIC), which revealed a statistically significant high-
er risk only in female AML, but not in other gender and
biological subgroups,4 was based on a relatively small
number of incident cases: only 671 out of 375,021 partici-
pants over 11.5 years of median follow up. The use of
orthogonal epidemiological approaches is a strength of the
study, as it attempts to mitigate some weaknesses of each
design. Registry-based studies have little patient selection
bias, providing results that are more comparable to real-
life scenarios. However, the quality of case identification
is likely to be sub-optimal; erroneous assignment of APL
to the general AML ICD code might "deplete" incident
cases and further reduce statistical power. Case-control
studies in the context of clinical trials, on the other hand,
offer the advantage of gold standard diagnosis but might
be affected by significant patient selection biases. This
may have counter-selected obese patients in the present
study, since the correlated comorbidities may be associat-
ed with limited access to clinical trials.
Another limitation of the study is that we could not pro-
vide the same degree of geographical homogeneity for
control subjects in the case-control studies. This may be
particularly relevant for the USA, known to have wide
state-specific differences in BMI distribution. However,
this variation is mainly due to demographic parameters,22
such as age, gender and race, and is, therefore, at least
partly accounted for in our multivariate analysis. We also
note that our US APL cohort includes a single patient of
hispanic ethnicity. Hispanics are considered at higher inci-
dence of APL, although some large studies based on
Surveillance, Epidemiology, and End Results (SEER) data
dispute this commonly held conclusion.23
Understanding the molecular mechanism causing
increased cancer risk in obese subjects is crucial for ade-
quate nutritional management in disease prevention, given
the sustained rise of obesity worldwide, particularly in
emerging economies. The possibility of matching tran-
scriptional and mutational profiles from TCGA to patient
clinical and BMI data provided an opportunity to generate
hypotheses grounded on actual data. However, extracting
biological significance from large molecular datasets
remains challenging. Shifting the analytical focus from sin-
gle genes to gene sets or pathways may allow signals to be
captured even when the changes affecting individual genes
are minimal, provided they are coherent. The gene set-
based method we used here for transcriptional analysis
does not assume equal variances, resulting in improved
sensitivity and specificity over similar competing
methods.15 Our main finding is the upregulation of several
genes involved in the metabolism of pro-inflammatory ω-
6 polyunsaturated fatty acids (PUFA, linoleic and arachi-
donic) in APL. These molecules are increased in the plasma
of metabolically impaired subjects, including the obese,24
and may lead to elevated production of derivative mole-
cules with multiple effects in signaling and inflammation,
enhancing leukemogenesis through several independent
mechanisms: direct growth promotion, generation of
genotoxic oxidative stress, immune modulation,18,25 and
generation of endogenous agonists for Peroxisome prolifer-
ator-activated receptors (PPAR).26 PPAR are known insulin
sensitizers27 and their transcriptional targets are up-regulat-
ed in APL (Online Supplementary Table S2); APL expressed
higher levels of insulin and IGF1 receptors, and its growth
may thus be favored by the increased insulin/IGF1 levels in
obese subjects.3,28 Elevated generation of PUFA-derived
eicosanoids by APL cells may also explain the association
between obesity and ATRA differentiation syndrome
(DS),10 as eicosanoids strongly promote leukocyte adhesion
and chemokine release in the lungs.29
Finally, the association between FLT3 mutations and a
higher BMI, although unconfirmed in the larger Spanish
cohort, is an intriguing finding that we think deserves addi-
tional research. FLT3 mutations are associated with specif-
ic metabolic dependencies which may be differentially
affected according to the systemic nutritional status.30 It
cannot be entirely ruled out that geographical differences
in dietary composition may account for the discrepancies
in the association between BMI and APL risk (weakest in
Spain) and FLT3 mutations (null in Spain). Consistent with
this highly speculative view, a recent EPIC substudy
revealed marked differences in nutritional patterns
between European nations. Despite sharing a theoretical
propensity for “Mediterranean” diets, Italy and Spain were
highly polarized, especially in terms of average polyunsat-
urated fatty acid consumption (3% vs. 38% of the partici-
pants in the highest quintile, respectively).31 More mecha-
nistic studies are needed to clarify whether FLT3 mutations
are favored by specific nutritional components.
In conclusion, based on evidence provided here, we pro-
pose including obesity among environmental factors
increasing risk for myeloid neoplasms and in particular
APL. Additional studies with experimental models will
clarify the molecular determinants of this relationship, and
test whether and how specific nutritional components like
PUFA can determine specific mutational and transcription-
al alterations able to influence the natural history of the
disease.
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